

CLOSE COMBAT: BRINGING THE IMMUNE SYSTEM IN TO DEFEAT MULTIPLE MYELOMA (MM)

LIVE
BROADCAST

FRIDAY 7 MAY 2021
16:30-18:00 CEST

WELCOME

It is our pleasure to invite you to this satellite symposium including a live panel discussion and Q&A with the faculty. The program will focus on the importance of the immune system and novel immunotherapies in the management of patients with MM.

Professor Mateos will discuss how different strategies harness the immune system to optimize treatments for MM. Professor Mikhael will provide the rationale for chimeric antigen receptor T-cell therapy in MM and describe the mechanism of action of these novel immunotherapeutic agents and their potential for treating patients with MM. Early clinical data show the promising efficacy of bispecific antibodies in relapsed/refractory MM. Professor van de Donk will look in close detail at the rationale, current clinical development, and future directions of these emerging immunotherapies.

Join us for what promises to be a stimulating, educational, and interactive symposium discussing key topics of interest for all those involved in the management of patients with MM.



PROGRAM

LEARNING OBJECTIVES

After attending this symposium delegates should be able to:

- Discuss the role of the immune system in optimizing treatments for MM
- Explain the potential role of CAR T-cell therapies in MM
- Describe the potential for bispecific monoclonal antibodies in the management of MM

5 mins **Welcome and introduction**
M Mohty

20 mins **Harnessing the immune system: optimizing treatments for MM**
MV Mateos

20 mins **New frontiers with CAR T-cell therapies in MM**
J Mikhael

20 mins **A new era of treatment with bispecific antibodies in MM**
N van de Donk

25 mins **Panel perspectives with Q&A**
All, moderated by M Mohty

SCIENTIFIC COMMITTEE

Mohamad Mohty, France (Moderator)
María-Victoria Mateos, Spain

FACULTY

Niels van de Donk, The Netherlands
Joseph Mikhael, USA

MEET OUR FACULTY



SCIENTIFIC COMMITTEE **MOHAMAD MOHTY**

Mohamad Mohty is Professor of Hematology and Head of the Hematology Department at the Saint-Antoine Hospital and Sorbonne University in Paris, France. He conducts translational research on novel agents in myeloma and has a clinical focus on reduced-toxicity conditioning regimens, immunotherapy, and other aspects of myeloma therapy. He is the past president and currently chairman of the scientific council of the European Society for Blood and Marrow Transplantation.



**DON'T WORRY IF YOU
MISSED OUR SYMPOSIUM
YOU CAN VIEW AN
ON-DEMAND VERSION
THROUGH COMy 2021.**

MEET OUR FACULTY



SCIENTIFIC COMMITTEE **MARÍA-VICTORIA MATEOS**

María-Victoria Mateos is Consultant Physician in the Hematology Department and Associate Professor of Medicine at the University of Salamanca, Spain. She is the director of the Myeloma Program and coordinates the Clinical Trials Unit in Salamanca's University Hospital Hematology Department.

She serves as coordinator of GEM (Spanish Myeloma Group), with direct involvement in the design and development of clinical trials. She has coordinated many clinical trials in elderly and smoldering multiple myeloma (MM) patients that have profoundly influenced current options for treating these patient populations.

She has published over 200 original papers in international journals. Her areas of interest include MM, the biology of plasma cells and the development of new drugs.



DON'T WORRY IF YOU MISSED OUR SYMPOSIUM YOU CAN VIEW AN ON-DEMAND VERSION THROUGH COMy 2021.

MEET OUR FACULTY



FACULTY

NIELS VAN DE DONK

Niels van de Donk is a Hematologist at the VU University Medical Center in Amsterdam, The Netherlands. He treats patients with a variety of hematological malignancies but has a special interest in the treatment of patients with multiple myeloma. Professor van de Donk is involved in translational research aimed at finding new targets for therapy, with a focus on immune therapy. Between January 2011 and January 2013, Professor van de Donk worked as a postdoctoral fellow at the Dana-Farber Cancer Institute in Boston, USA. He is also an ad hoc reviewer for journals including *Blood*, *Leukemia*, and *Haematologica*, and is Associate Editor of the *Netherlands Journal of Hematology*. Part of Professor van de Donk's time is dedicated to teaching medical students, residents, and colleagues about hematological diseases with an emphasis on multiple myeloma, and he frequently gives presentations at regional, national, and international conferences.



**DON'T WORRY IF YOU
MISSED OUR SYMPOSIUM
YOU CAN VIEW AN
ON-DEMAND VERSION
THROUGH COMy 2021.**

MEET OUR FACULTY



FACULTY **JOESPH MIKHAEL**

Dr Joseph Mikhael is a Professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope Cancer Center in Phoenix, USA. He is also the Chief Medical Officer of the International Myeloma Foundation (IMF) and serves as a Councillor on the ASH Executive Committee.

Dr Mikhael specializes clinically in plasma cell disorders, namely multiple myeloma, amyloidosis, and Waldenstrom's macroglobulinemia. He is the Principal Investigator for many clinical trials, primarily in relapsed multiple myeloma, and his other clinical research interests include pharmaco-economics, communication skills, and media relations. Dr Mikhael has published over 150 peer-reviewed articles in these fields and lectures internationally on a regular basis. Dr Mikhael recently led the first-ever ASCO Guidelines in multiple myeloma and serves on the editorial board of the *Journal of Clinical Oncology*.

Dr Mikhael is deeply involved in training future researchers and acts as a mentor to junior faculty worldwide. He now spends nearly 20% of his time in the third world developing collaborations in myeloma and finding ways to enhance access to novel agents.



DON'T WORRY IF YOU MISSED OUR SYMPOSIUM YOU CAN VIEW AN ON-DEMAND VERSION THROUGH COMy 2021.

Organised and supported by Janssen Pharmaceutical Companies of Johnson & Johnson in EMEA
Janssen Pharmaceutica NV
Turnhoutseweg 30, 2340 Beerse, Belgium

CP-220314
Date of preparation: March 2021
Copyright © 2021 Janssen Pharmaceutica NV

Janssen Pharmaceutica NV

Hematology
Medical
Education

janssen Oncology
PHARMACEUTICAL COMPANIES OF Johnson & Johnson